Engineered Bacterial Membranes as Next-Generation Platforms for Cancer Immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Bacterial membranes, including outer membrane vesicles and bacterial ghosts, are recognized for their potential in immunotherapy.
• They naturally possess components that can stimulate the immune system, acting as adjuvants.

Purpose of the Study:

• To explore the use of engineered bacterial membranes as multifunctional immunotherapeutic platforms for cancer treatment.
• To investigate how combining tumor antigens with pathogen-associated molecular patterns (PAMPs) on bacterial membranes enhances anti-tumor immunity.

Main Methods:

• Engineering bacterial membranes by genetically fusing tumor antigens with PAMPs (e.g., LPS, flagellin, CpG motifs).
• Utilizing advanced genetic fusion systems (Lpp-OmpA, ClyA, Ag43, SpyTag/SpyCatcher) and modifying lipid A.
• Developing hybrid scaffolds and evaluating bacterial membrane fragments and ghosts.

Main Results:

• Engineered bacterial membranes effectively activate dendritic cells and promote antigen crosspresentation, leading to cytotoxic T-cell memory.
• Preclinical studies demonstrated reprogramming of the tumor microenvironment, inducing Th1-polarized immunity and pyroptotic tumor cell death.
• These platforms showed synergistic effects with checkpoint blockade, chemotherapy, and phototherapy in various cancer models (melanoma, lung, breast, glioblastoma).

Conclusions:

• Bacterial membranes represent a versatile and programmable platform for next-generation cancer vaccines, bridging innate and adaptive immunity.
• Engineered bacterial membranes offer a safe, modular, and scalable approach for cancer immunotherapy.
• Integration with AI and CRISPR technologies paves the way for clinical translation of these immunotherapeutic strategies.